# An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

> **NCT02591914** · PHASE1 · COMPLETED · sponsor: **Retinal Consultants of Arizona** · enrollment: 30 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Fovista™
- **DRUG:** Lucentis®
- **DRUG:** Avastin®
- **DRUG:** Eylea®

## Key facts

- **NCT ID:** NCT02591914
- **Lead sponsor:** Retinal Consultants of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-05-18
- **Final completion:** 2016-05-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591914, "An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02591914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*